State of Alaska Department of Revenue Has $5.55 Million Stock Position in Becton, Dickinson and Company $BDX

State of Alaska Department of Revenue decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.2% during the 2nd quarter, HoldingsChannel reports. The fund owned 32,248 shares of the medical instruments supplier’s stock after selling 1,400 shares during the period. State of Alaska Department of Revenue’s holdings in Becton, Dickinson and Company were worth $5,554,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the first quarter worth $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company during the first quarter worth $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of analyst reports. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus raised their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday. They set a “sector perform” rating and a $211.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $213.09.

Insider Activity

In related news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,965 shares of company stock worth $551,536. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $184.59 on Monday. The stock has a 50-day simple moving average of $188.27 and a 200 day simple moving average of $188.49. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The stock has a market capitalization of $52.91 billion, a price-to-earnings ratio of 33.20, a P/E/G ratio of 1.49 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period in the previous year, the business posted $3.50 earnings per share. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.